JP6305443B2 - 移植片の移植寛容のための組み合わされた臓器及び造血細胞 - Google Patents

移植片の移植寛容のための組み合わされた臓器及び造血細胞 Download PDF

Info

Publication number
JP6305443B2
JP6305443B2 JP2015560191A JP2015560191A JP6305443B2 JP 6305443 B2 JP6305443 B2 JP 6305443B2 JP 2015560191 A JP2015560191 A JP 2015560191A JP 2015560191 A JP2015560191 A JP 2015560191A JP 6305443 B2 JP6305443 B2 JP 6305443B2
Authority
JP
Japan
Prior art keywords
days
less
cells
months
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015560191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016517394A5 (enExample
JP2016517394A (ja
Inventor
ストロバー，サミュエル
ロウスキー，ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2016517394A publication Critical patent/JP2016517394A/ja
Publication of JP2016517394A5 publication Critical patent/JP2016517394A5/ja
Application granted granted Critical
Publication of JP6305443B2 publication Critical patent/JP6305443B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015560191A 2013-02-26 2014-02-07 移植片の移植寛容のための組み合わされた臓器及び造血細胞 Active JP6305443B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361769596P 2013-02-26 2013-02-26
US61/769,596 2013-02-26
PCT/US2014/015394 WO2014133729A1 (en) 2013-02-26 2014-02-07 Combined organ and hematopoietic cells for transplantation tolerance of grafts

Publications (3)

Publication Number Publication Date
JP2016517394A JP2016517394A (ja) 2016-06-16
JP2016517394A5 JP2016517394A5 (enExample) 2017-03-09
JP6305443B2 true JP6305443B2 (ja) 2018-04-04

Family

ID=51388802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015560191A Active JP6305443B2 (ja) 2013-02-26 2014-02-07 移植片の移植寛容のための組み合わされた臓器及び造血細胞

Country Status (9)

Country Link
US (21) US9504717B2 (enExample)
EP (3) EP4729128A3 (enExample)
JP (1) JP6305443B2 (enExample)
KR (2) KR102491343B1 (enExample)
CN (2) CN113476478A (enExample)
AU (2) AU2014221330B2 (enExample)
CA (1) CA2902098A1 (enExample)
GB (2) GB2526228B (enExample)
WO (1) WO2014133729A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113476478A (zh) 2013-02-26 2021-10-08 小利兰·斯坦福大学托管委员会 实现移植物移植耐受的联合器官和造血细胞
MX376790B (es) * 2013-03-14 2025-03-07 Univ Johns Hopkins Células presentadoras de antígeno artificiales de nanoescala.
US20190000885A1 (en) * 2015-11-30 2019-01-03 The General Hospital Corporation Treatment with angiogenin to enhance hematopoietic reconstitution
AU2017241626B2 (en) 2016-03-28 2022-03-31 Gallant Pet, Inc. Viable cell compositions, and methods related to same
EP3765044A4 (en) 2018-03-12 2021-12-08 Medeor Therapeutics, Inc. TREATMENT METHODS FOR NON-CANCERIOUS DISORDERS USING HEMATOPOIETIC CELLS
US10881692B2 (en) * 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
US10842821B2 (en) 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
WO2020047236A1 (en) * 2018-08-30 2020-03-05 The Regents Of The University Of California Mobilization and collection of peripheral blood hematopoietic stem cells from deceased donors
US11813376B2 (en) 2018-09-18 2023-11-14 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
US20200086004A1 (en) * 2018-09-18 2020-03-19 Medeor Therapeutics, Inc. Methods of making cellular compositions derived from deceased donors to promote graft tolerance
CA3112320A1 (en) * 2018-09-18 2020-03-26 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
US11435350B2 (en) 2018-09-18 2022-09-06 Medeor Therapeutics, Inc. Methods of analysis of blood from deceased donors
WO2020121988A1 (ja) * 2018-12-09 2020-06-18 国立大学法人北海道大学 免疫抑制作用又は免疫寛容誘導作用を評価する方法、及び免疫寛容誘導剤
JP7395174B2 (ja) * 2018-12-09 2023-12-11 国立大学法人北海道大学 免疫抑制作用又は免疫寛容誘導作用を評価する方法、及び免疫寛容誘導剤
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
US20220305057A1 (en) * 2019-06-06 2022-09-29 Medeor Therapeutics, Inc. Methods of making cellular products by post- mortem mobilization and harvesting of hematopoietic cells
AU2020379319A1 (en) * 2019-11-05 2022-06-23 Yeda Research And Development Co. Ltd. Use of veto cells in treatment of T cell mediated autoimmune diseases
US20230201256A1 (en) * 2020-05-21 2023-06-29 Medeor Therapeutics, Inc. Calcineurin inhibitor to improve cd3+cell survival to thereby facilitate engraftment of donor cd34+ cells in a recipient
MX2022016039A (es) 2020-06-23 2023-05-04 Zelarion Malta Ltd Anticuerpos anti-cd2.
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
US20240024362A1 (en) * 2020-09-30 2024-01-25 The Board Of Trustees Of The Leland Stanford Junior University Donor hematopoietic cell chimerism and organ and tissue transplantation and autoimmune tolerance
EP4229183A4 (en) 2020-10-14 2024-12-11 Ossium Health, Inc. Compositions and methods for extraction of mesenchymal stem cells
EP4228406A4 (en) 2020-10-14 2024-11-13 Ossium Health, Inc. SYSTEMS AND METHODS FOR BONE MARROW EXTRACTION AND CRYOPRESERVATION
EP4262831A4 (en) 2020-12-18 2025-01-01 Ossium Health, Inc. CELLULAR THERAPY PROCESSES
CN112669992B (zh) * 2020-12-30 2024-06-11 中国人民解放军总医院 单倍体造血干细胞移植atg个体化用药量的计算方法
WO2022159824A1 (en) * 2021-01-25 2022-07-28 Ossium Health, Inc. Methods of cell therapies
US12245355B2 (en) 2021-02-19 2025-03-04 Mevion Medical Systems, Inc. Gantry for a particle therapy system
CN113813454B (zh) * 2021-08-30 2022-09-09 四川大学华西医院 一种采集器官捐献供体血液的方法
WO2023036745A1 (en) * 2021-09-07 2023-03-16 Zelarion Malta Limited Method and composition for inducing tolerance
US12584107B2 (en) 2022-01-20 2026-03-24 3T Biosciences, Inc. T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells
EP4633647A1 (en) * 2022-12-16 2025-10-22 The Regents of the University of California Retro-active (delayed) immunological tolerance induction in patients with pre-existing solid organ transplants
WO2025231133A1 (en) * 2024-04-30 2025-11-06 University Of Kentucky Research Foundation GENERATION OF TOLEROGENIC ORGANS USING NORMOTHERMIC or HYPOTHERMIC PERFUSION PUMP WITH TREG CELL BASED IMMUNOTHERAPY WITH OR WITHOUT STEM CELLS

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6006752A (en) 1996-05-09 1999-12-28 The General Hospital Corporation Mixed chimerism and tolerance
DE69841058D1 (de) 1997-11-14 2009-09-24 Gen Hospital Corp Behandlung von hämatologischen störungen
IL137614A0 (en) * 1998-02-04 2001-07-24 Gen Hospital Corp An inhibitor of a costimulatory pathway and hematopoietic stem cells for promoting graft acceptance
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting
WO2001078653A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Graft rejection inhibition with ccr2 inhibitors
JP2002092615A (ja) 2000-09-20 2002-03-29 Fujitsu Ltd 画像処理装置及び画像形成装置
WO2002040640A2 (en) * 2000-11-14 2002-05-23 The University Of Louisville Research Foundation, Inc. Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc)
US20030031652A1 (en) * 2001-04-16 2003-02-13 Bernhard Hering Systems and methods for inducing mixed chimerism
US20050118142A1 (en) * 2001-08-01 2005-06-02 Ildstad Suzanne T. Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
US20060127399A1 (en) * 2004-09-13 2006-06-15 Defu Zeng Compositions and methods for inducing chimerism in a subject
US7811815B2 (en) 2004-11-15 2010-10-12 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic uses of allogeneic myeloid progenitor cells
EP1904101A4 (en) * 2005-06-08 2011-06-15 Univ Duke ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION
EP2514315A3 (en) 2005-08-24 2012-11-07 Yeda Research and Development Co. Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
WO2007033221A2 (en) * 2005-09-13 2007-03-22 The General Hospital Corporation Methods and compositions for inhibition of immune responses
US8632768B2 (en) * 2008-05-30 2014-01-21 University Of Louisville Research Foundation, Inc. Human facilitating cells
US9290813B2 (en) * 2009-12-02 2016-03-22 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
US20110137375A1 (en) 2009-12-03 2011-06-09 Mcbride Keith System and method for detection of inversion and eversion of the foot using a multi-chamber insole
CN104906139B (zh) * 2011-01-10 2020-10-23 小利兰·斯坦福大学托管委员会 异源造血干细胞移植的增强
JP2015508101A (ja) * 2012-02-21 2015-03-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｃｄ３４＋細胞を含む薬学的組成物
CN113476478A (zh) 2013-02-26 2021-10-08 小利兰·斯坦福大学托管委员会 实现移植物移植耐受的联合器官和造血细胞

Also Published As

Publication number Publication date
US11116794B2 (en) 2021-09-14
US11648264B2 (en) 2023-05-16
US11020428B2 (en) 2021-06-01
US20190358257A1 (en) 2019-11-28
CN105188755A (zh) 2015-12-23
US10080769B2 (en) 2018-09-25
US20190336528A1 (en) 2019-11-07
US20190192562A1 (en) 2019-06-27
US11040067B2 (en) 2021-06-22
HK1217450A1 (zh) 2017-01-13
EP4729128A2 (en) 2026-04-22
US10258648B2 (en) 2019-04-16
US10076542B2 (en) 2018-09-18
WO2014133729A1 (en) 2014-09-04
GB2558680A (en) 2018-07-18
US20190192561A1 (en) 2019-06-27
US11458165B2 (en) 2022-10-04
US20180221409A1 (en) 2018-08-09
AU2018250369A1 (en) 2018-11-08
US10603340B2 (en) 2020-03-31
US11123367B2 (en) 2021-09-21
GB2558680B (en) 2018-10-03
US20200254015A1 (en) 2020-08-13
US20140243577A1 (en) 2014-08-28
US10159694B2 (en) 2018-12-25
GB201516407D0 (en) 2015-10-28
EP2961431A4 (en) 2016-01-20
US20190091262A1 (en) 2019-03-28
US20190298762A1 (en) 2019-10-03
US20180243337A1 (en) 2018-08-30
US9504717B2 (en) 2016-11-29
KR102491343B1 (ko) 2023-01-27
US20180193379A1 (en) 2018-07-12
JP2016517394A (ja) 2016-06-16
US10183043B2 (en) 2019-01-22
US20170119819A1 (en) 2017-05-04
AU2018250369B2 (en) 2020-09-03
US12303532B2 (en) 2025-05-20
GB2526228B (en) 2017-05-03
US20190083530A1 (en) 2019-03-21
US20220362291A1 (en) 2022-11-17
CA2902098A1 (en) 2014-09-04
US11129849B2 (en) 2021-09-28
GB201704460D0 (en) 2017-05-03
US9561253B2 (en) 2017-02-07
US20180193380A1 (en) 2018-07-12
US20180344766A1 (en) 2018-12-06
US20190000877A1 (en) 2019-01-03
US11007220B2 (en) 2021-05-18
US20180221410A1 (en) 2018-08-09
EP3804735A1 (en) 2021-04-14
US11426429B2 (en) 2022-08-30
EP4729128A3 (en) 2026-07-08
AU2014221330B2 (en) 2018-10-04
US10555971B2 (en) 2020-02-11
CN113476478A (zh) 2021-10-08
KR20210030501A (ko) 2021-03-17
US9974807B2 (en) 2018-05-22
EP2961431A1 (en) 2016-01-06
KR20150132196A (ko) 2015-11-25
US11439662B2 (en) 2022-09-13
US20150272993A1 (en) 2015-10-01
AU2014221330A1 (en) 2015-10-22
US20170106086A1 (en) 2017-04-20
GB2526228A (en) 2015-11-18
US20210196754A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
US12303532B2 (en) Combined organ and hematopoietic cells for transplantation tolerance of grafts
EP4221727A1 (en) Donor hematopoietic cell chimerism and organ and tissue transplantation and autoimmune tolerance

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180306

R150 Certificate of patent or registration of utility model

Ref document number: 6305443

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250